Medication Summary

Until a few years ago, 4 principal medications were used for partial seizures: phenytoin, carbamazepine,
valproate, and phenobarbital. However, a number of newer medications have been approved by the FDA.
Some of these newer AEDs are approved as monotherapy, but how they compare with the older AEDs is not
known.
The initial choice of medication depends on many factors, including side-effect profile, dosage schedule, and
comorbid conditions. The major VA trials did not show any significant difference in seizure control among the 4
older AEDs. Adverse effects were greater with phenobarbital and with primidone.
Single-drug therapy is the goal, and the dosage of each medication prescribed should be increased until either
seizures are controlled or adverse effects occur.
The new AEDs have a class-wide warning about suicidal ideation mandated by the FDA, which arose from 4
suicides amongst 40,000 patients exposed to AEDs. The patient should be evaluated for mood changes, which
may need treatment.

Anticonvulsants
Class summary
These agents prevent seizure recurrence and terminate clinical and electrical seizure activity.

Carbamazepine (Tegretol, Carbatrol, Epitol, Equetro)

Carbamazepine affects sodium channels during sustained, rapid, repetitive firing. The extended
release form is preferred (Tegretol XR or Carbatrol) because of twice-daily dosing, which improves
compliance and leads to more stable blood levels. No intravenous (IV) formulation is available.

Phenytoin (Dilantin, Phenytek)

Phenytoin is one of oldest drugs known for treatment of seizures. In young women, it can coarsen
facial features and can cause hirsutism and gingival hyperplasia. In addition, frequent blood-level
determinations are required in patients taking the drug, because of nonlinear pharmacokinetics. Longterm use has been associated with peripheral neuropathy and osteopenia.

Valproate (Depacon, Depakene, Depakote, Depacote ER, Stavzor)

This anticonvulsant is effective for a broad spectrum of seizure types; it is believed to exert its
anticonvulsant effect by increasing gamma-aminobutyric acid (GABA) levels in the brain. Valproate is
approved for monotherapy or adjunctive therapy for partial seizures and generalized tonic-clonic
seizures. Depakene is available as a capsule or syrup, and Depakote is available as a tablet or
sprinkle.

Lamotrigine (Lamictal, Lamictal ODT, Lamictal XR)

Lamotrigine is a newer AED; it was approved as an adjunctive therapy and a crossover monotherapy
for partial seizures. It also blocks sodium channels during sustained, rapid, repetitive neuronal firing.
The drug is FDA approved for children younger than age 16 years only for Lennox-Gastaut syndrome;
it is not FDA approved for children with partial seizures, because of an increased incidence of rash.

Gabapentin (Neurontin)
Gabapentin is approved by the FDA as an adjunctive therapy for partial seizures. It is structurally
related to GABA but does not affect GABA directly, although it is thought to modulate the calcium
channel.

Topiramate (Topamax)

Topiramate is approved by the FDA as a monotherapy or an adjunctive therapy for partial seizures and
symptomatic generalized seizures. It exerts action by 4 mechanisms: sodium-channel blockade,
enhancement of GABA activity, antagonism of AMPA/kainate-type glutamate excitatory receptors, and
weak inhibition of carbonic anhydrase.
Tiagabine (Gabitril)
This drug enhances GABA activity by inhibiting uptake in neurons and astrocytes. Tiagabine can be
used as an add-on therapy for partial seizures. It has been known to exacerbate seizures with spikewave stupor. Some patients who were receiving off label and never had seizures had seizures induced
with tiagabine when it was used with another medication, which lowers the seizure threshold.
Zonisamide (Zonegran)
Zonisamide is approved in the United States for adjunctive use in the treatment of partial seizures. It
has been studied extensively in Japanese and European trials for primary generalized seizures. The
drug blocks T-type calcium currents and prolongs sodium-channel inactivation. It is also a weak
carbonic anhydrase inhibitor. In monotherapy, it has a long half-life (70 h).
Oxcarbazepine (Trileptal)
Oxcarbazepine is approved by the FDA as a monotherapy and as an adjunctive therapy for partial
epilepsy in adults and children aged 2-16 years. It blocks sodium-activated channels during sustained,
rapid, repetitive firing. Oxcarbazepine has antiepileptic activity, but its monohydroxy (MHD) metabolite
is the most active compound. Oxcarbazepine is different from carbamazepine, which generates a 1011 epoxide metabolite.
Levetiracetam (Keppra)
This drug was approved by the FDA in 1999 as an add-on therapy for partial seizures. It is also FDA
approved as an add-on therapy for juvenile myoclonic epilepsy and primary generalized tonic-clonic
seizures. The drug's mechanism of action is thought to be related to the binding of levetiracetam to
presynaptic vesicle protein. The medication has a favorable adverse effect profile overall, except for
behavioral changes.
Felbamate (Felbatol)
Felbamate is approved for medically refractory partial seizures and Lennox-Gastaut syndrome. It has
multiple mechanisms of action, including blockade of the glycine site of the N-methyl-D-aspartate
(NMDA) receptor, potentiation of GABAergic activity, and inhibition of voltage-sensitive sodium
channels. However, felbamate has a high rate of life-threatening side effects, so the benefits and risks
of the drug need to be carefully addressed.
Pregabalin (Lyrica)
Pregabalin was approved in 2005 for adjunctive use in partial seizures in adults. Its mechanism of
action (calcium-channel modulation) is similar to that of gabapentin, but it is more potent and has
linear pharmacokinetics
Rufinamide (Banzel)
Rufinamide is structurally unrelated to other current antiepileptics. It modulates sodium-channel
activity, particularly through prolongation of the channel's inactive state. The drug significantly slows
sodium-channel recovery and limits sustained, repetitive firing of sodium-dependent action potentials.
Rufinamide is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut
syndrome.
Ethotoin (Peganone)
Ethotoin may act in the motor cortex where it may inhibit the spread of seizure activity. The activity of
the brain stem centers responsible for the tonic phase of grand mal seizures may also be inhibited.
Vigabatrin (Sabril)
Vigabatrin is a structural derivative of GABA. Its mechanism of action is unknown. Vigabatrin binds
with high affinity to the alpha2-delta site (a calcium channel subunit). In vitro, it reduces the calciumdependent release of several neurotransmitters, possibly by modulating calcium channel function. It is
FDA approved for neuropathic pain associated with diabetic peripheral neuropathy or postherpetic
neuralgia and as adjunctive therapy in partial-onset seizures.
Lacosamide (Vimpat)

Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in

stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing. It is
indicated for adjunctive therapy for partial-onset seizures.